Leslie Chong - Imugene CEO, Managing Director
| IUGNF Stock | USD 0.06 0.01 16.00% |
CEO
Ms. Leslie Chong is Chief Executive Officer, Managing Director of the Company. Most recently, Ms Chong was a Senior Clinical Program Leader at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the worlds most successful biotech companies with a strong oncology franchise including the bestselling breast cancer drug Herceptin. since 2018.
| Tenure | 6 years |
| Phone | 61 3 9824 5254 |
| Web | https://www.imugene.com |
Imugene Management Efficiency
The company has return on total asset (ROA) of (0.2148) % which means that it has lost $0.2148 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3718) %, meaning that it generated substantial loss on money invested by shareholders. Imugene's management efficiency ratios could be used to measure how well Imugene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Brian Pedlar | Covalon Technologies | N/A | |
| Gilles Gagnon | Ceapro Inc | 62 | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 |
Imugene Limited Leadership Team
Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA ASiA, Ex Chairman | ||
| Charles Walker, Non-Executive Director | ||
| Anthony Good, VP Research | ||
| Paul Hopper, Executive Chairman of the Board | ||
| Nathan CA, Joint Sec | ||
| Ursula Wiedermann, Chief Scientific Officer | ||
| PharmD MBA, Chief Officer | ||
| Justyn Stedwell, Joint Company Secretary | ||
| Leslie Chong, CEO, Managing Director | ||
| Ursula McCurry, VP Operations | ||
| Mark Marino, Chief Medical Officer | ||
| Lesley Russell, Non-Executive Director | ||
| Phillip Hains, Joint Company Secretary | ||
| Giovanni Selvaggi, Chief Officer | ||
| ACA BSc, Chief Officer | ||
| Jens Eckstein, Non-Executive Director | ||
| Dr BSc, Chief Officer |
Imugene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Imugene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 737.79 M | |||
| Shares Outstanding | 6.42 B | |||
| Shares Owned By Insiders | 15.40 % | |||
| Shares Owned By Institutions | 8.67 % | |||
| Price To Book | 8.51 X | |||
| Price To Sales | 61.84 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Imugene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Imugene's short interest history, or implied volatility extrapolated from Imugene options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |